Literature DB >> 15856183

Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.

Takeki Uehara1, Hiroshi Watanabe, Fumio Itoh, Satoshi Inoue, Hikaru Koshida, Masuhisa Nakamura, Jyoji Yamate, Toshiyuki Maruyama.   

Abstract

The present study was designed to characterize the nephrotoxicity induced by the antineoplastic platinum complex nedaplatin (NDP) in rats of different ages in comparison with cisplatin (CDDP). A single dose of 15 mg/kg NDP or 7.5 mg/kg CDDP was administered intravenously to 8-, 11-, or 15-week-old male and female SD rats, which were then sacrificed after ten days. Body weight decreases were observed for both drugs, in direct relation to age. CDDP treatment markedly increased urinary excretion of NAG, gamma-GTP, LDH and protein, with peaks on day 4 and complete or partial recovery on day 7; NDP increased NAG, LDH and protein excretion, but to a lesser extent, and these elevations were generally more marked for females. CDDP increased plasma creatinine and BUN in males and females of all age groups at necropsy. No apparent changes were seen following NDP treatment except in the 15-week-old rats. These results also show that NDP is less nephrotoxic than CDDP. CDDP-treated rats showed remarkable proximal tubular lesions in the renal cortex and corticomedullary region, and the papillary lesions were minor. On the other hand, the NDP-induced nephrotoxicity was morphologically characterized by hyaline droplet changes (electron microscopically, hyperplasia of lysosomes), necrosis or hyperplasia of the collecting duct epithelium in the renal papilla and the epithelium covering the papilla. Cortical lesions, indicated by slight tubular dilatation, were found only in the animals with papillary lesions. In summary, NDP is a promising second-generation platinum complex with reduced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856183     DOI: 10.1007/s00204-005-0648-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  12 in total

Review 1.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

Review 2.  Emergence of biomarkers in nephropharmacology.

Authors:  Enver Khan; Vecihi Batuman; Juan J L Lertora
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

3.  Silk Reservoirs for Local Delivery of Cisplatin for Neuroblastoma Treatment: In Vitro and In Vivo Evaluations.

Authors:  Burcin Yavuz; Jasmine Zeki; Jordan Taylor; Kristin Harrington; Jeannine M Coburn; Naohiko Ikegaki; David L Kaplan; Bill Chiu
Journal:  J Pharm Sci       Date:  2019-03-21       Impact factor: 3.534

4.  Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma.

Authors:  Toru Fujioka; Toshiaki Yasuoka; Masae Koizumi; Hiroki Tanaka; Hisashi Hashimoto; Motoo Nabeta; Koji Koizumi; Yuko Matsubara; Katsuyuki Hamada; Keiichi Matsubara; Tomihiro Katayama; Akihiro Nawa
Journal:  Mol Clin Oncol       Date:  2012-09-25

5.  Comparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics.

Authors:  Takeki Uehara; Jyoji Yamate; Mikinori Torii; Toshiyuki Maruyama
Journal:  J Toxicol Pathol       Date:  2011-06-30       Impact factor: 1.628

6.  Nedaplatin: a radiosensitizing agent for patients with cervical cancer.

Authors:  Seiji Mabuchi; Tadashi Kimura
Journal:  Chemother Res Pract       Date:  2010-09-21

7.  Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.

Authors:  Masateru Fujiwara; Fumiaki Isohashi; Seiji Mabuchi; Yasuo Yoshioka; Yuji Seo; Osamu Suzuki; Iori Sumida; Kazuhiko Hayashi; Tadashi Kimura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-11-26       Impact factor: 2.724

8.  A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix.

Authors:  Guangwen Yuan; Lingying Wu; Manni Huang; Nan Li; Jusheng An
Journal:  Radiat Oncol       Date:  2014-02-18       Impact factor: 3.481

9.  Prospective phase II study of image-guided local boost using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancer.

Authors:  Kentaro Nishioka; Shinichi Shimizu; Nobuo Shinohara; Yoichi M Ito; Takashige Abe; Satoru Maruyama; Rumiko Kinoshita; Keiichi Harada; Noboru Nishikawa; Naoki Miyamoto; Rikiya Onimaru; Hiroki Shirato
Journal:  Jpn J Clin Oncol       Date:  2013-12-02       Impact factor: 3.019

10.  Anticancer effects of dihydromyricetin on the proliferation, migration, apoptosis and in vivo tumorigenicity of human hepatocellular carcinoma Hep3B cells.

Authors:  Lianggui Jiang; Wen-Chu Ye; Zuobiao Li; Yongguang Yang; Wei Dai; Mingyi Li
Journal:  BMC Complement Med Ther       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.